Literature DB >> 29030201

SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.

Robert M Bell1, Derek M Yellon2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29030201     DOI： 10.1016/S2213-8587(17)30314-5

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  19 in total

Review 1.  Review of the veteran affairs diabetes trial: Lessons learned.

Authors:  Kelvin Tran; Peter Reaven
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

2.  Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.

Authors:  Xin-Lin Zhang; Qing-Qing Zhu; Yu-Han Chen; Xue-Ling Li; Fu Chen; Jian-An Huang; Biao Xu
Journal:  J Am Heart Assoc       Date:  2018-01-20       Impact factor: 5.501

Review 3.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.

Authors:  Gary D Lopaschuk; Subodh Verma
Journal:  JACC Basic Transl Sci       Date:  2020-06-22

4.  Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

Authors:  Brendon L Neuen; Toshiaki Ohkuma; Bruce Neal; David R Matthews; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Mehul Desai; Qiang Li; Hsiaowei Deng; Norm Rosenthal; Meg J Jardine; George Bakris; Vlado Perkovic
Journal:  Circulation       Date:  2018-10-09       Impact factor: 29.690

5.  The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection-evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology.

Authors:  Sean M Davidson; Sapna Arjun; Maryna V Basalay; Robert M Bell; Daniel I Bromage; Hans Erik Bøtker; Richard D Carr; John Cunningham; Arjun K Ghosh; Gerd Heusch; Borja Ibanez; Petra Kleinbongard; Sandrine Lecour; Helen Maddock; Michel Ovize; Malcolm Walker; Marlene Wiart; Derek M Yellon
Journal:  Basic Res Cardiol       Date:  2018-10-11       Impact factor: 17.165

6.  Cardiorenal protective effect of sodium-glucose cotransporter 2 inhibitors and mitochondrial function.

Authors:  Hong Kyu Lee
Journal:  J Diabetes Investig       Date:  2019-01-23       Impact factor: 4.232

7.  SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart.

Authors:  Ven G Lim; Robert M Bell; Sapna Arjun; Maria Kolatsi-Joannou; David A Long; Derek M Yellon
Journal:  JACC Basic Transl Sci       Date:  2019-01-30

8.  Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation.

Authors:  Alex Ali Sayour; Sevil Korkmaz-Icöz; Sivakkanan Loganathan; Mihály Ruppert; Viktor Nabil Sayour; Attila Oláh; Kálmán Benke; Maik Brune; Rita Benkő; Eszter Mária Horváth; Matthias Karck; Béla Merkely; Tamás Radovits; Gábor Szabó
Journal:  J Transl Med       Date:  2019-04-16       Impact factor: 5.531

Review 9.  Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.

Authors:  Utkarsh Ojha; Lenisse Reyes; Florence Eyenga; Diane Oumbe; Justyna Watkowska; Henock Saint-Jacques
Journal:  Am J Cardiovasc Drugs       Date:  2021-06-30       Impact factor: 3.571

10.  Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.

Authors:  Silvio E Inzucchi; Kamlesh Khunti; David H Fitchett; Christoph Wanner; Michaela Mattheus; Jyothis T George; Anne Pernille Ofstad; Bernard Zinman
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.